Commentary on prevention of cardiovascular complications in diabetes mellitus as novel inidicationfor Diabeton MR
https://doi.org/10.14341/2072-0351-5524
Abstract
Current article presents commentary on official inclusion of cardiovascular prophylaxis in indications for Diabeton MR therapy. The paper features extensive review of data from ADVANCE (Action in Diabetes and Vascular Disease: PretarAx and DiamicroN Modified Release Controlled Evaluation) trial and its comparative analysis with other major randomized studies of intensive glycemic control in patients with type 2 diabetes mellitus.
References
1. Инструкция по применению лекарственного препарата для медицинского применения Диабетон® MВ, таблетки с модифицированным высвобождением, 60 мг. Изменение № 4 от 14 февраля 2011 года. ЛСР-006030/09-140211.
2. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12; 358(24): 2560-2572.
3. Zoungas S, Chalmers J, Patel A, et al. Intensive glucose control is renoprotective in type 2 diabetes: new analyses from ADVANCE. Abstracts of 46th annual meeting of the European Association for the Study of Diabetes, 2010. Diabetologia. 2010; 53(Suppl1): S98.
4. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-2559. Epub 2008 Jun 6.
5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-139. Epub 2008 Dec 17.
6. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation. 2000 May 2;101(17):2047-2052.
7. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010 Jun;33(6):1389- 1394.
8. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Tials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009 Jan 20;119(2):351-357. Epub 2008 Dec 17.
9. Zoungas S, Chalmers J, Kengne AP, Pillai A, Billot L, de Galan B, Marre M, Neal B, Harrap S, Poulter N, Patel A. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010 Aug;89(2):126-133. Epub 2010 Jun 11.
10. Шестакова МВ, Викулова ОК. Результаты открытой наблю- дательной программы DIAMOND. Сахарный диабет. 2011; 3(52): 96-102.
11. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, Novials A, Rottiers R, Rutten GE, Shaw KM. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004 Aug;34(8):535-542.
12. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994 Dec;11(10):974-980.
13. Veitch PC, Clifton-Bligh RJ. Long-acting sulfonylureas - long-acting gypoglycaemia. Med J Aust. 2004 Jan 19;180(2):84-85.
14. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group (DCCT). N Engl J Med. 1993 Sep 30;329(14):977-986.
15. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-2653.
16. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-853.
17. Holman RR, Paul SK, Bethel MA, Mattews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes mellitus. N Engl J Med. 2008 Oct 9;359(15):1577-1589. Epub 2008 Sep 10.
18. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep- Oct;15(6):540-559.
19. Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, Мкртумян АМ, Петунина НА, Сухарева ОЮ. Консенсус совета экспертов Российской ас- социации эндокринологов по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа. Са- харный диабет. 2011; 4(53):6-16.
Review
For citations:
Vikulova O.K. Commentary on prevention of cardiovascular complications in diabetes mellitus as novel inidicationfor Diabeton MR. Diabetes mellitus. 2012;15(2):84-88. (In Russ.) https://doi.org/10.14341/2072-0351-5524
Views:
691
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
